SRR1320916
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.396
- PANCREAS_BETA_CELLS+0.386
- INTERFERON_GAMMA_RESPONSE+0.279
- KRAS_SIGNALING_DN+0.242
- ALLOGRAFT_REJECTION+0.213
- APICAL_SURFACE+0.188
- INFLAMMATORY_RESPONSE+0.174
- SPERMATOGENESIS+0.130
- IL2_STAT5_SIGNALING+0.096
- KRAS_SIGNALING_UP+0.051
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.573
- MYC_TARGETS_V1-0.565
- MYC_TARGETS_V2-0.468
- G2M_CHECKPOINT-0.444
- E2F_TARGETS-0.436
- DNA_REPAIR-0.429
- MITOTIC_SPINDLE-0.399
- UNFOLDED_PROTEIN_RESPONSE-0.381
- ADIPOGENESIS-0.370
- PI3K_AKT_MTOR_SIGNALING-0.341
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1429725 | GTEX | — | 0.940 |
| 2 | SRR1446892 | GTEX | — | 0.911 |
| 3 | SRR1421198 | GTEX | — | 0.909 |
| 4 | SRR1413454 | GTEX | — | 0.896 |
| 5 | SRR1325927 | GTEX | — | 0.890 |
| 6 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.889 |
| 7 | SRR8942994 | — | — | 0.889 |
| 8 | MNG450 | — | — | 0.881 |
| 9 | MNG1098 | — | — | 0.879 |
| 10 | SRR650162 | — | — | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.396 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.386 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.279 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.242 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.213 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.188 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.174 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.096 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.051 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.045 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.025 | Idelalisib | — uncovered |